AGP Executive Report
Last update: an hour agoVaccine & Pharma Finance: Valneva reported €64.0M in first-half 2026 product sales, reaffirmed full-year guidance of €135–150M, and said it has a solid €121.5M cash position as it moves through a restructuring program, with regulatory decisions for its Lyme disease vaccine candidate expected within the next 12 months. Urban Health & Climate: A new look at urban heat islands warns that hot-humid cities in the tropics can’t always afford fixes like shade, green roofs, lighter surfaces, and better street airflow—especially as El Niño threatens record temperatures, putting vulnerable residents at higher risk. Public Health & Drug Policy (Mauritius): An editorial argues Mauritius needs a broader, more sustained strategy to tackle its drug crisis beyond headline-grabbing arrests, stressing fair process and safeguards while the investigation into a high-profile case unfolds.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
